Free shipping $200+ · Order by 2pm CT, ships today from Tulsa, OK · Research Use Only — Not for human consumption · Documentation you can verify beats claims you have to trust · Questions? (405) 814-0022

The short answer: tirzepatide is a dual agonist that activates the GIP and GLP-1 receptors, and it is FDA-approved (Mounjaro, Zepbound). Retatrutide is a triple agonist that activates those same two receptors plus the glucagon receptor, and it is still investigational in Phase 3 trials. Both come from Eli Lilly, both are 39-amino-acid peptides, and both are given once a week in trials.

Below: the full side-by-side, what the extra glucagon activity is meant to do, what the published trials have reported for each, and what is still unknown.

Retatrutide vs tirzepatide: side-by-side

TirzepatideRetatrutide
Receptors activatedGIP + GLP-1GIP + GLP-1 + glucagon
TypeDual agonistTriple agonist
DeveloperEli LillyEli Lilly
Code nameLY3298176LY3437943
Length39 amino acids39 amino acids
Molecular weightAbout 4,813 g/molAbout 4,731 g/mol
Half-lifeAbout 5 daysAbout 6 days
Strongest receptorGIP (binds about as strongly as native GIP)GIP (more potent than native GIP)
StatusFDA-approved (2022 onward)Investigational, Phase 3 (TRIUMPH)
Brand namesMounjaro, ZepboundNone

The key difference: the glucagon receptor

Everything else follows from one design choice. Tirzepatide works on the two incretin receptors, GIP and GLP-1. Those mainly reduce how much energy comes in: they increase fullness, slow stomach emptying, and improve glucose-dependent insulin release.

Retatrutide adds the glucagon receptor, which works on the other side of the energy balance. Glucagon receptor activation increases energy expenditure and drives fat burning in the liver. The idea behind a triple agonist is to reduce intake and increase output at the same time, while the GLP-1 and GIP activity keeps glucagon’s blood-sugar-raising effect in check.

That is also why liver fat is a point of interest for retatrutide: glucagon acts directly on the liver, and a 2024 sub-study reported large reductions in liver fat in people with fatty liver disease.

How they are built

The two molecules are close relatives:

  • Both are GIP-based peptides of 39 amino acids, engineered so one chain can activate more than one receptor.
  • Both use non-natural amino acids (such as Aib) to resist breakdown by the enzyme DPP-4.
  • Both carry a C20 fatty diacid side chain that binds albumin in the blood, which is what gives each a half-life measured in days rather than minutes.

The differences are in the sequence tuning. Tirzepatide is balanced toward GIP, with weaker GLP-1 activity than native GLP-1. Retatrutide is tuned to be strongest at GIP and weaker than the native hormones at both GLP-1 and glucagon.

What the trials have reported

TirzepatideRetatrutide
Key obesity trialSURMOUNT-1 (Phase 3, NEJM 2022)Phase 2 (NEJM 2023)
Trial length72 weeks48 weeks
Participants2,539338
Mean weight reduction, highest dose20.9% (placebo 3.1%)24.2% (placebo 2.1%)

Important caveat: these numbers come from different trials with different lengths, sizes, populations and phases. Retatrutide’s figure is from a smaller Phase 2 study; tirzepatide’s is from a large Phase 3 study. They cannot be compared directly. The only reliable way to rank two drugs is a head-to-head trial, like SURMOUNT-5, which compared tirzepatide with semaglutide. Retatrutide’s Phase 3 program is where its full efficacy and safety picture will come from.

Side effects compared

Both compounds have shown the same broad pattern in trials: the most common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation), usually mild to moderate and most frequent while the dose is being increased. Retatrutide’s Phase 2 trials also reported dose-dependent increases in heart rate that peaked and then eased.

The difference is how much is known. Tirzepatide has years of approved use, full prescribing information and a boxed warning about thyroid C-cell tumors seen in rodents. Retatrutide’s longer-term safety profile will only be established once its Phase 3 data are complete and reviewed.

Approval status

  • Tirzepatide: approved for type 2 diabetes (Mounjaro, 2022), chronic weight management (Zepbound, 2023), and obstructive sleep apnea in adults with obesity (Zepbound, 2024).
  • Retatrutide: not approved. It is in the TRIUMPH Phase 3 program, with the first results reported starting in late 2025. Approval would require a completed program, an FDA submission and review.

Where semaglutide fits

These three drugs form a progression: semaglutide (GLP-1 only) → tirzepatide (GIP + GLP-1) → retatrutide (GIP + GLP-1 + glucagon). Each step adds a receptor. For the full background on each, see What Is Tirzepatide?, What Is Retatrutide? and our semaglutide overview.

Frequently asked questions

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates GIP and GLP-1 receptors and is FDA-approved as Mounjaro and Zepbound. Retatrutide activates GIP, GLP-1 and glucagon receptors and is still investigational in Phase 3.

Is retatrutide stronger than tirzepatide?

Retatrutide’s Phase 2 weight results were larger than tirzepatide’s Phase 3 results, but the trials differed in design, length and population. No head-to-head results had been published at the time of writing.

Are retatrutide and tirzepatide made by the same company?

Yes. Both were developed by Eli Lilly: tirzepatide as LY3298176 and retatrutide as LY3437943.

Is retatrutide FDA approved like tirzepatide?

No. Tirzepatide has been approved since 2022; retatrutide is still investigational.

Sources

  • Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
  • Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
  • Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism, 2022.
  • Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020.
  • Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine, 2024.
  • Mounjaro and Zepbound U.S. prescribing information, Eli Lilly and Company.

This article is for educational purposes only and is not medical advice. Retatrutide is an investigational compound that is not approved for human use.